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Abstract
Aims/hypothesis Within a trial of intensive treatment of peo-
ple with screen-detected diabetes, we aimed to assess a poten-
tial spillover effect of the trial intervention on incident cardio-
vascular disease (CVD) and all-cause mortality among people
who screened positive on a diabetes risk questionnaire but
who were normoglycaemic.
Methods In the Anglo–Danish–Dutch Study of Intensive
Treatment In People with Screen-Detected Diabetes in
Primary Care (ADDITION)-Denmark trial, 175 general prac-
tices were cluster-randomised into: (1) screening plus routine
care of individuals with screen-detected diabetes (control
group); or (2) screening plus training and support in intensive
multifactorial treatment of individuals with screen-detected
diabetes (intervention group). We identified all individuals
who screened positive on a diabetes risk questionnaire in
ADDITION-Denmark but were normoglycaemic following
biochemical testing for use in this secondary analysis. After
a median 8.9 years follow-up, we used data from national
registers to compare rates of first CVD events and all-cause
mortality in individuals in the routine care group with those in
the intensive treatment group.
Results In total, 21,513 individuals screened positive for high
risk of diabetes but were normoglycaemic on biochemical
testing in ADDITION-Denmark practices between 2001 and
2006 (10,289 in the routine care group and 11,224 in the
intensive treatment group). During 9 years of follow-up, there
were 3784 first CVD events and 1748 deaths. The incidence
of CVD was lower among the intensive treatment group com-
pared with the routine care group (HR 0.92 [95% CI 0.85,
0.99]). This association was stronger among individuals at
highest CVD risk (heart SCORE≥ 10; HR 0.85 [95% CI
0.75, 0.96]). There was no difference in mortality between
the two treatment groups (HR 1.02 [95% CI 0.92, 1.14]).
Conclusions/interpretation Training of general practitioners
to provide target-driven intensive management of blood glu-
cose levels and other cardiovascular risk factors showed some
evidence of a spillover effect on the risk of CVD over a 9 year
period among individuals at high risk of diabetes. The effect
was particularly pronounced among those at highest risk of
CVD. There was no effect on mortality.
Trial registration: ClinicalTrials.gov NCT00237549
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Introduction
Screening for type 2 diabetes inevitably identifies more people
at high risk of developing diabetes and cardiovascular disease
(CVD) than those with undiagnosed prevalent disease. Little
is known about these high risk individuals following their
participation in a screening programme. While well-
established guidelines for the treatment of diabetes exist, most
countries do not specify how to treat individuals who screen
positive following completion of a diabetes risk questionnaire
but are normoglycaemic on biochemical testing.
In the Anglo–Danish–Dutch Study of Intensive Treatment
In People with Screen-Detected Diabetes in Primary Care
(ADDITION)-Denmark trial (ClinicalTrial.gov registration
no. NCT00237549) [1], 175 general practices were cluster-
randomised to routine care or to receive training and support
in the implementation of an intensive treatment programme
for individuals with screen-detected diabetes. This included
lifestyle intervention and CVD risk factor management. The
intervention was associated with a significant increase in
redeemed cardioprotective medication and a non-significant
17% risk reduction in CVD events among individuals with
screen-detected diabetes over 5 years of follow-up [2].
Given the favourable increase in cardioprotective medication
observed in the intensive treatment practices, we wanted to
investigate whether the education and guidelines we offered
may have also had an impact on the management of patients
with normal blood glucose levels following screening.
In order to assess a potential spillover effect of the trial
intervention among practices taking part in ADDITION-
Denmark, we compared rates of first CVD events and all-
cause mortality among people who screened positive on the
diabetes risk questionnaire but who were normoglycaemic on
biochemical testing in the routine care (control) and intensive
treatment trial groups.
Methods
ADDITION-Denmark consists of two phases: (1) a stepwise
screening programme; and (2) a cluster-randomised parallel-
group trial comparing the effects of intensive multifactorial
treatment with routine care among individuals with screen-
detected type 2 diabetes [1, 2]. In brief, between 2001 and
2006, we performed a population-based stepwise screening
programme among people aged 40–69 years without known
diabetes in 175 general practices in Denmark. Eligible indi-
viduals were sent a diabetes risk score questionnaire [3] with
an invitation to visit their family doctor for a diabetes test
and a cardiovascular risk assessment (heart SCORE) [4] if
they scored ≥ 5 points (maximum 15 points) on the risk
questionnaire. The diabetes risk score questionnaire esti-
mates diabetes risk using age, sex, BMI, known hyperten-
sion, leisure time physical activity and family history of
diabetes [3]. The heart SCORE estimates fatal CVD risk
using age, sex, smoking, systolic blood pressure and total
cholesterol [4]. Participants who attended a screening
appointment underwent measurement of height, weight,
blood pressure, random blood glucose (RBG), total choles-
terol and HbA1c. Individuals with an RBG ≥ 5.5 mmol/l or
HbA1c ≥ 5.8% (40 mmol/mol) were invited to return to the
practice for further testing. The WHO 1999 criteria, based
on a standard OGTT, were used to diagnose diabetes [5].
Participants diagnosed with type 2 diabetes were subse-
quently managed according to the treatment regimen to
which their practice had been allocated: routine care
(control) or intensive treatment. Ethical approval for the
trial was granted by the Region Midt Ethical Committee,
Denmark. As this was a registry-based study using
anonymised data, participants did not give informed con-
sent. This approach was approved by the Danish Data
Protection Agency and the Danish Health and Medicine
Authority.
For those diagnosed with diabetes, general practitioners
and nurses received training and support in delivering inten-
sive treatment via small group or practice-based educational
meetings where treatment targets/algorithms, lifestyle advice
and supporting evidence were discussed [2]. Intensive treat-
ment practices received additional funding to support the de-
livery of care, which included target-driven management of
hyperglycaemia and blood pressure and cholesterol levels by
medical treatment and promotion of healthy lifestyles, based
on the stepwise regimen used in the Steno-2 study and other
trial results. In the routine care (control) group, general prac-
titioners were advised to follow Danish national recommen-
dations for diabetes treatment and received no further follow-
up. In both groups, practitioners were encouraged to treat
normoglycaemic individuals with a heart SCORE ≥5, accord-
ing to Danish guidelines [6].
In this secondary analysis, in order to assess the potential
spillover effect of the intervention, we identified individuals
who underwent screening as part of ADDITION-Denmark
and who were normoglycaemic on biochemical testing.
Normoglycaemia in our study refers to individuals with an
RBG <5.5 mmol/l and HbA1c ≤6% (42mmol/mol) at the first
visit/blood test, and people with fasting blood glucose
< 5.6 mmol/l and 2 h blood glucose following an OGTT
<7.8 mmol/l. Participants were followed for a median of
8.9 years to 31 December 2011, when national registers were
searched for information on vital status and a composite of
first event of cardiovascular death (ICD-10 codes I60 to I69,
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I20 to I25, and I46), non-fatal ischaemic heart disease (ICD-
10 codes I20 to I25, and I46) or non-fatal stroke (ICD-10 code
I60 to I69).
Statistical analysis Characteristics were summarised sepa-
rately in the intensive treatment and routine care
(control) groups. Date of entry to the study was set as
date of invitation to screening. Individuals were censored
on the date of first event following invitation for screen-
ing (for the incident CVD analysis), upon death, or on the
31 December 2011 (final date of follow-up), depending
on which occurred earliest. HRs comparing incident
CVD events and all-cause mortality between the groups
were estimated with a Cox proportional hazards regres-
sion model and we accounted for clustering at the general
practitioner level. We tested the proportional hazards
assumption by including a variable for treatment by time
interaction in the Cox regression model (p > 0.05). We
also examined these associations in all individuals with
a heart SCORE of ≥ 0 to < 5, ≥5 to <10, and ≥ 10. All
analyses were completed using Stata Version 14.1
(StataCorp, College Station, TX, USA).
Table 1 Characteristics of normoglycaemic individuals following diabetes screening in the ADDITION-Denmark study (n = 21,513), by treatment
group
NGT NGT and heart
SCORE ≥ 0 to < 5
NGT and heart
SCORE ≥ 5 to < 10
NGT and heart
SCORE ≥ 10
Routine care
group
(n= 10,289)
Intensive
treatment group
(n= 11,224)
Routine
care group
(n= 4890)
Intensive
treatment group
(n= 5347)
Routine
care group
(n = 2450)
Intensive
treatment group
(n= 2603)
Routine care
group
(n = 1795)
Intensive
treatment group
(n= 1925)
Male sex, n (%) 5251 (51.0) 5749 (51.2) 1627 (33.3) 1745 (32.6) 1608 (65.6) 1705 (65.5) 1515 (84.4) 1625 (84.4)
Age (SD) 59.1 (6.9) 59.1 (7.0) 55.8 (6.4) 55.8 (6.4) 62.1 (5.1) 62.2 (4.8) 65.1 (4.0) 65.2 (4.1)
Education level, n (%)
0–10 years 3191 (31.5) 3608 (32.6) 1453 (30.1) 1613 (30.5) 835 (34.6) 872 (34.0) 611 (34.7) 672 (35.5)
10–15 years 4297 (42.4) 4555 (41.1) 2075 (43.0) 2189 (41.4) 1005 (41.6) 1028 (40.0) 735 (41.8) 796 (42.1)
≥ 15 years 2640 (26.1) 2908 (26.3) 1297 (26.9) 1486 (28.1) 575 (23.8) 668 (26.0) 414 (23.5) 424 (22.4)
Previous CVD, n (%) 470 (4.6) 495 (4.4) 166 (3.4) 167 (3.1) 141 (5.8) 146 (5.6) 97 (5.4) 100 (5.2)
Redeemed anti-hypertensive medication,
n (%)a
Year 2000 2429 (23.6) 2663 (23.7) 1126 (23.0) 1199 (22.4) 608 (24.8) 667 (25.6) 457 (25.5) 506 (26.3)
Year 2005 4124 (40.7) 4383 (39.6) 1749 (36.1) 1814 (34.2) 1041 (43.2) 1100 (42.9) 904 (52.0) 977 (52.8)
Year 2010 5265 (54.3) 5692 (53.9) 2256 (47.6) 2411 (46.8) 1317 (58.0) 1406 (57.6) 1120 (70.8) 1198 (71.4)
Redeemed glucose-lowering medication,
n (%)a
Year 2000b
Year 2005 21 (0.2) 21 (0.2) 9 (0.2) 12 (0.2) 5 (0.2) b 6 (0.3) 5 (0.3)
Year 2010 156 (1.6) 184 (1.7) 74 (1.6) 86 (1.7) 34 (1.5) 43 (1.8) 39 (2.5) 33 (2.0)
Redeemed lipid-lowering medication,
n (%)a
Year 2000 383 (3.7) 374 (3.3) 138 (2.8) 135 (2.5) 125 (5.1) 112 (4.3) 86 (4.8) 100 (5.2)
Year 2005 1573 (15.5) 1692 (15.3) 602 (12.4) 638 (12.0) 452 (18.7) 487 (19.0) 369 (21.2) 401 (21.7)
Year 2010 3035 (31.3) 3238 (30.7) 1247 (26.3) 1341 (26.0) 779 (34.3) 845 (34.6) 652 (41.2) 685 (40.8)
HR for CVD (95% CI) 0.92 (0.85, 0.99) 0.90 (0.80, 1.02) 0.98 (0.84, 1.13) 0.85 (0.75, 0.96)
HR for all-cause
mortality (95% CI)
1.02 (0.92, 1.14) 1.07 (0.89, 1.30) 0.88 (0.75, 1.04) 1.06 (0.90, 1.26)
Data are presented as n (%), mean (SD) or HR (95% CI)
Please note that numbers in the three heart SCORE groups do not add up to the total cohort size (n= 21,513) because of missing data for some
individuals, which prevented us from computing the heart SCORE. Similarly, numbers for education do not add up to the total cohort size because of
missing data
a Numbers for cardioprotective medication in years 2005 and 2010 were calculated using the individuals who were alive at the beginning of that year as
the denominator
b Numbers for redeemed glucose-lowering medication are too small to report (Statistics Denmark regulations)
NGT, normal glucose tolerance
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Results
Between 2001 and 2006, 21,513 individuals were found with
normal blood glucose following screening in ADDITION-
Denmark practices (10,289 in the routine care [control] group
and 11,224 in the intensive treatment group). The groups had
similar baseline characteristics, with similar proportions of
men (51%) and numbers of individuals with >15 years edu-
cation (26%) and previous CVD (∼4.5%; Table 1). The mean
age in both groupswas 59 years. The proportion of individuals
redeeming lipid-lowering, glucose-lowering and anti-
hypertensive medication was similar throughout follow-up
(Table 1).
Median (interquartile range) duration of follow-up was
8.9 years (8.2–10.0). During follow-up, there were 1904
CVD events (17.0%) in the intensive treatment group and
1880 (18.3%) events in the routine care group. The incidence
of CVD was lower among the intensive treatment group com-
pared with the routine care group (HR 0.92 [95% CI 0.85,
0.99]; Table 1 and Fig. 1a). This association was more pro-
nounced among individuals with a heart SCORE ≥10 (HR
0.85 [95% CI 0.75, 0.96]). There were 923 deaths (8.2%) in
the intensive treatment group and 825 (8.0%) deaths in the
routine care group. Of these, 125 (13.5%) and 106 (12.8%)
were CVD-related deaths in the intensive treatment and rou-
tine care groups, respectively. The incidence of all-cause mor-
tality was similar between the two treatment groups (HR 1.02
[95% CI 0.92, 1.14]; Table 1 and Fig. 1b) across all levels of
CVD risk.
Discussion
We found some evidence for a spillover effect from the inten-
sive treatment of people with screen-detected diabetes to those
with normal blood glucose levels. Among normoglycaemic
individuals, the incidence of CVD was significantly lower in
the intensive treatment compared with the routine care
(control) group. There was no difference in the mortality
experience of the two groups.
We previously showed that the training of general practi-
tioners in intensive treatment of diabetes in the ADDITION-
Denmark study had no spillover effect on progression to diabe-
tes in individuals with impaired fasting glucose or impaired
glucose tolerance [7]. There are very few other studies exam-
ining the spillover effect of a trial intervention in general prac-
tice with which to compare our results. In general, interventions
targeting healthcare professionals seem to be beneficial only if
baseline HbA1c control is poor [8, 9]. Our finding of reduced
rates of CVD among individuals with normoglycaemia may
therefore be considered somewhat surprising. However, as in-
dividuals who have a positive diabetes risk score are at high risk
of CVD and mortality whether or not subsequent testing shows
them to have diabetes [10], this is a welcome observation.
While we did not find a difference in the rates of redeemed
medication between groups, we hypothesise that training and
support of general practitioners in the intensive treatment arm of
the trial may have improved the management of lifestyle be-
haviour, and maybe medication adherence, among patients
identified at high risk but without diabetes on biochemical test-
ing. One-third of screen-detected individuals with diabetes in
ADDITION-Denmark reported that they had stopped smoking
at the 5 year follow-up. Furthermore, this whole cohort lost an
average of 2 kg in weight [2]. Similar behavioural responses
among individuals identified at high CVD risk may provide a
potential mechanism for the observed CVD risk reduction
alongside prescribed treatment.
Overall, there was evidence of suboptimal routine treat-
ment among individuals who screened positive for high risk
of diabetes but were normoglycaemic upon biochemical test-
ing in ADDITION-Denmark. Under routine care, general
practitioners were advised to treat individuals at high CVD
risk e.g. with a heart SCORE ≥5. However, even among peo-
ple with a heart SCORE ≥10, the medication data show that
less than 22% of individuals were on lipid-lowering treatment
in 2005 and less than 42% in 2010. All participants in this
group should have been prescribed lipid-lowering drugs
according to national guidelines [5]. As well as evidence of
‘undertreatment’, there also appeared to be a considerable de-
lay in starting treatment among this high-risk population.
While our intervention was associated with a small abso-
lute risk reduction for individuals with normoglycaemia in the
entire cohort, there was a clinically meaningful risk reduction
among individuals at highest CVD risk (heart SCORE ≥10).
We suggest that the reduction in cardiovascular events might
have been greater if general practitioners were convinced to
treat according to guidelines for cardiovascular risk
management.
b
0.10
0.20
0.30
0
C
um
ul
at
iv
e 
pr
ob
ab
ili
ty
 o
f
al
l-c
au
se
 m
or
ta
lit
y
0 2 4 6 8 10
Duration of follow-up (years)
a
0.10
0.20
0.30
0
C
um
ul
at
iv
e 
pr
ob
ab
ili
ty
 o
f
co
m
po
si
te
 C
V
D
 e
ve
nt
0 2 4 6 8 10
Duration of follow-up (years)
Fig. 1 Cumulative incidence of (a) CVD and (b) all-cause mortality
among individuals with normal glucose tolerance in the ADDITION-
Denmark intensive treatment and routine care groups (2001–2011).
This figure is unadjusted. Routine care group, blue; intensive treatment
group, red. Heart SCORE ≥ 0 to <5, dashed line; heart SCORE ≥ 5 to <10,
dot/dash line; heart SCORE ≥10, solid line
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In the current study, the Danish registry system allowed
us to investigate the long-term experience of individuals
found to have normal glucose tolerance following screen-
ing in ADDITION-Denmark practices between 2001 and
2011. Trial groups were well balanced for patient level
characteristics at baseline. Outcome ascertainment was
very robust. The Danish National Death Registry esti-
mates 100% coverage of mortality based on death certif-
icates, while the National Patient Registry includes 99.4%
of discharges from Danish hospitals. The vast majority of
participants were white European, the main ethnic group
in Denmark, which limits generalisability to other set-
tings. It would have been interesting to examine trends
in lifestyle factors, such as smoking, diet and physical
activity, which might have accounted for some of the dif-
ference in CVD rates we observed, but data were not
available for this cohort.
In conclusion, training of general practitioners to provide
target-driven intensive management of blood glucose levels
and other cardiovascular risk factors showed some evidence
of a spillover effect on the risk of CVD among the
normoglycaemic population. The effect was particularly pro-
nounced among those at highest risk of CVD.
Acknowledgements We gratefully acknowledge the contribution of all
participants, practice nurses and general practitioners in the ADDITION-
Denmark study. With special thanks to M. Pedersen (Department of
Public Health, University of Aarhus, Aarhus, Denmark) for her help with
retrieving data from Statistics Denmark.
Data availability The data used in this paper was a combination of data
obtained from the ADDITION study and data from national Danish
Registers at Denmark Statistics (DST). The ADDITION study data were
obtained after a written application to the data owner, A. Sandbæk
(Institute of Public Health, Aarhus University, Aarhus, Denmark;
annelli.sandbaek@ph.au.dk). Data from DST were made available
following an application to DST (www.dst.dk/en/TilSalg/
Forskningsservice). Data from ADDITION and DST were merged by
DST and analyses were performed via a secure Virtual Private Network
(VPN) connection. In accordance with the Danish Act of processing of
personal data, future interested researchers must perform the steps men-
tioned above to obtain access to the data.
Funding ADDITION-Denmark was supported by the national health
services in the counties of Copenhagen, Aarhus, Ringkøbing, Ribe and
South Jutland in Denmark, the Danish Council for Strategic Research, the
Danish Research Foundation for General Practice, Novo Nordisk
Foundation, the Danish Centre for Evaluation and Health Technology
Assessment, the diabetes fund of the National Board of Health, the
Danish Medical Research Council and the Aarhus University Research
Foundation. The trial has been supported by unrestricted grants from
Novo Nordisk A/S, Novo Nordisk Scandinavia AB, Novo Nordisk UK,
ASTRADenmark, Pfizer Denmark, GlaxoSmithKline Pharma Denmark,
Servier DenmarkAS andHemoCueDenmark AS. The study sponsor was
not involved in the design of the study; the collection, analysis and
interpretation of data; writing the report; or the decision to submit the
report for publication.
Duality of interest DRW and RKS are supported by the Danish
Diabetes Academy, which is funded by the Novo Nordisk Foundation.
RKS is further supported by the Aarhus Institute of Advanced Studies.
DRW reports receiving lecture fees from Novo Nordisk A/S and Steno
Diabetes Center. DRW, MEJ and TL hold shares in Novo Nordisk A/S.
TL reports receiving a travel reimbursement for attending meetings on
early detection and treatment of diabetes in 2015 and 2016. These meet-
ings were held by the International Diabetes Federation (IDF) and
Primary Care Diabetes Europe, and were sponsored by Astra Zeneca.
AS reports receiving lecture fees for providing continuing medical edu-
cation to general practitioners. MEJ is the principal investigator of an
investigator initiated trial sponsored by Astra Zeneca and reports receiv-
ing lecture fees from Astra Zeneca. All other authors declare that there is
no duality of interest associated with their contribution to this manuscript.
Contribution statement NHB and TL had full access to all of the data
in the study and take responsibility for the accuracy of the data analysis.
TL acts as guarantor for this paper. AS, TL and KB-J designed the
ADDITION-Denmark study and are principal investigators for the trial.
DRW, MEJ, AS and TL developed the study proposal. NHB, DRW and
TL participated in the acquisition of the data from Statistics Denmark.
NHB analysed the data. RKS drafted the report. DRW, RKS, KB-J, MEJ,
AS and TL participated in the interpretation of the data and critical revi-
sion of the report for important intellectual content. All co-authors gave
final permission for this version of the manuscript to be published.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ,
Wolffenbuttel BH, Rutten G (2000) The ADDITION study: pro-
posed trial of the cost-effectiveness of an intensive multifactorial
intervention on morbidity and mortality among people with Type 2
diabetes detected by screening. Int J Obes Relat Metab Disord
24(Suppl 3):S6–S11
2. Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early
intensive multifactorial therapy on 5-year cardiovascular outcomes
in individuals with type 2 diabetes detected by screening
(ADDITION-Europe): a cluster-randomised trial. Lancet 378:
156–167
3. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T,
Borch-Johnsen K (2004) A Danish diabetes risk score for targeted
screening: the Inter99 study. Diabetes Care 27:727–733
4. Perk J, De Backer G, Gohlke H et al (2012) European Guidelines
on cardiovascular disease prevention in clinical practice. The Fifth
Joint Task Force of the European Society of Cardiology and Other
Societies on Cardiovascular Disease Prevention in Clinical Practice
(constituted by representatives of nine societies and by invited ex-
perts). Eur Heart J 33:1635–1701
5. WHO (1999) definition, diagnosis, and classification of diabetes
mellitus and its complications: report of a WHO consultation. In:
WHO (ed) Geneva. Avai lable from http: / /apps.who.
int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf,
accessed 13 February 2017
6. DanskSelskabforAlmenMedicin(1998)Forebyggelseafhjertesygdomi
almen praksis –med særligt henblik på dyslipidæmi (Prevention of heart
Diabetologia
disease in general practice – with particular focus on dyslipidaemia).
Updated 2002 and 2007. In: Dansk Selskab for Almen Medicin (ed)
Odder. Available from http://www.dsam.dk/files/9/iskaemisk_hjerte_
kar_sygdom_2007.pdf, accessed 13February 2017
7. Rasmussen SS, Glumer C, Sandbaek A, Lauritzen T, Borch-
Johnsen K (2008) General effect on high-risk persons when general
practitioners are trained in intensive treatment of type 2 diabetes.
Scand J Prim Health Care 26:166–173
8. Lauritzen T, Sandbaek A, Carlsen AH, Borch-Johnsen K (2012)
All-cause mortality and pharmacological treatment intensity fol-
lowing a high risk screening program for diabetes. A 6.6 year
follow-up of the ADDITION study, Denmark. Prim Care
Diabetes 6:193–200
9. Tricco AC, Ivers NM, Grimshaw JM et al (2012)
Effectiveness of quality improvement strategies on the man-
agement of diabetes: a systematic review and meta-analysis.
Lancet 379:2252–2261
10. Spijkerman A, Griffin S, Dekker J, Nijpels G, Wareham NJ (2002)
What is the risk of mortality for people who are screen positive in a
diabetes screening programme but who do not have diabetes on
biochemical testing? Diabetes screening programmes from a public
health perspective. J Med Screen 9:187–190
Diabetologia
